Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Citius Oncology, Inc.NASDAQ: CTOR
Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q2 FY2026 weighted avg shares (diluted) of 100.03M shares rose 39.8% year over year, ahead of the +20.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 14.4% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.
Context
- Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +39.8% holds above the trailing-twelve-month pace of +20.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 73.27M USD
- Year-over-year change
- +2.4%
- 3-year CAGR
- -6.7%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 73.27M | +2.4% |
| FY2024 | 2024-09-30 | 71.55M | -20.0% |
| FY2023 | 2023-09-30 | 89.48M | -0.8% |
| FY2022 | 2022-09-30 | 90.16M | — |
Weighted Avg Shares (Diluted) vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 weighted avg shares (diluted) of 85M shares is the 4th highest of the 10 companies compared; the peer median is 21.96M shares.
- Its year-over-year change of +20.9% is the 5th highest of 10, against a peer median of +12.5%.
- Over three fiscal years its annual growth of -6.7% compares with a peer median of +18.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 149.39M | +1085.6% | +313.6% | |
| LTM Mar 2026 | 119.09M | +1.0% | +7.1% | |
| LTM Mar 2026 | 88.77M | +1552.7% | +496.0% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | 85M | +20.9% | -6.7% |
| LTM Mar 2026 | 57.24M | +5.3% | +16.2% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | 21.96M | +12.5% | +11.8% |
| LTM Mar 2026 | 12.87M | +10.8% | +5.6% | |
| LTM Mar 2026 | 10.28M | +60.8% | +42.2% | |
| LTM Mar 2026 | 8.99M | +10.4% | +18.0% | |
| LTM Mar 2026 | 5.81M | +40.8% | +70.9% | |
| Peer median (excluding CTOR) | 21.96M | +12.5% | +18.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.